

2025 Bioshares Biotech Summit - PROGRAM

Wednesday 6 August

4.00pm - 6.00pm	Registration Open (Grand Chancellor Hotel, ground floor)
6.30pm	CEO Dinner (Biotech Company CEOs only), Rockwall Bar & Grill (upstairs)
6.30pm	CFO Dinner (details TBA)
6.30pm	Peasants Dinner (Contact: stuart.roberts@pittstreetresearch.com)

Thursday 7 August (Hotel Grand Chancellor)

7.00am - 8.30am	Registration Open
8.30am	Introduction, Housekeeping
8.40am	Sector Analysis, Thomas Wakim, Healthcare Analyst at Bell Potter

Session 1: Leading the Way

To open this year's Summit company presentations, we will hear from some of the leading, breakout companies in the sector. These companies are either moving into pivotal studies, sealing multiple partnerships, launching new products, or accelerating the growth in their profitable businesses.

9.00am - 9.30am	Wayne Paterson, CEO of Anteris Technologies Global Corporation
9.30am - 9.55am	Nina Webster, CEO of Dimerix
9.55am - 10.20am	Brad O'Connor, CEO of Cogstate
10.20am - 10.45am	Lachlan Hay, acting CEO of Clinuvel Pharmaceuticals
Chair: David Nayagam, E&P	



10.45am-11.30am **Break**

Session 2: Finding the Next 10x

Which drug developer will provide the next 10x in share price growth, following on from Telix, Neuren and Dimerix in recent years? This session will feature five companies that are positioned for very strong growth, but only if the clinical results are very good.

11.30am - 11.50am	Chris Burns, CEO of Amplia Therapeutics
11.50am - 12.10pm	Rebecca McQualter, CEO of Chimeric Therapeutics
12.10pm - 12.30pm	Gary Phillips, CEO of Syntara
12.30pm - 12.50pm	Kilian Kelly, CEO of Cynata Therapeutics
12.50pm - 12.55pm	Patricio Sepulveda, CEO of Amplio Biotechnology
Chair: Michelle Ng, IQVIA	



1.00pm-2.00pm **Lunch**

Session 3: Deal Making – The Real Story

A chance to hear and learn from four serious deal-makers about the approaches, the twist and turns, and the closing of major biotech deals.

2.00pm - 2.40pm	Panelists: Wayne Paterson (CEO of Anteris), Nina Webster (CEO of Dimerix), Brent Barnes (CEO of Clever Culture Systems), Anthony Filippis (CEO of Neurotech International)
Chair: Andrew Kelly, BioPacific Partners	

Session 4: The Drug Development Journey

Bringing a new drug to market is not always a linear process. There are many learnings along the way, and programs may need to be adjusted. This session will hear from two companies seeking to bring their novel therapies to market, their experiences to date, and the opportunities ahead.

2.40pm - 3.00pm	Steven Gourlay, CEO of Actinogen Medical
3.00pm - 3.20pm	Leslie Chong, CEO of Imugene
3.20pm - 3.25pm	Sander Bangma, CEO of Navier Medical



3.30pm - 4.00pm **The Mike Hirshorn Address**

Dr Jakob Dupont (Executive Partner at Sofinnova Investments, Non-Executive Director of Imugene)

4.00pm - 4.40pm **Break**

Session 5: What the Heck Biotech

There are novel approaches being taken by some biotechs, potentially ahead of the curve. Diagnosing autism via a smartphone, using psychedelics to treat mental health disorders, photodynamic therapies for tumour destruction, cannabinoids for sleep, and will sealing the gut lining help address many neurodegenerative disorders?

4.40pm - 5.00pm	Thian Chew, CEO of Invion
5.00pm - 5.20pm	Paul Gavin, CEO of Avecho Biotechnology
5.20pm - 5.40pm	Henk-Jan Boele, CEO of Blinklab
5.40pm - 6.00pm	Jean-Pascal Zambaux, CEO of PLL Therapeutics
6.00pm - 6.20pm	Jason Carroll, CEO of Tryptamine Therapeutics
6.20pm	Daniel Perkins , CEO of Neurala Biosciences
Chair: Mark Pachacz (Bioshares)	
6.25pm	The Blake Award for Excellence ("The Blakey")
6.30pm	End of Day 1



7.30pm - 11.00pm **Cocktail Reception** (Franklin Wharf, across from conference venue)



Friday 8 August

9.00am - 9.45am **Master Class 1: D&O Insurance: Lifeboat or Luxury?**
Panelists: Josh Meyer (**Avatar Brokers**), Meredith Lieu (**Liberty Specialty Markets**), Kevin Nhan (**Liberty Specialty Markets**), Gemma Cooper (**Liberty Specialty Markets**)
Chair Lis Boyce (**Piper Alderman**)

The panel will discuss the ins and outs of D & O insurance including: How side A, B and C operate; A shareholder class action case study; Exposures associated with IPO's; Capital raising; and the current marketplace for D & O insurance.

Sponsored by **Liberty Specialty Markets**



9.45am - 10.25am **Master Class 2: What Investors Are Saying: Creating and Maintaining an Investible Patent Portfolio**

FB Rice shares insights from a recent investor survey on what makes a patent portfolio attractive. The session will cover the role of IP strategy in investment decisions and practical ways to manage diminishing patent term.

Panelists: Dr Ian Rourke, Dr Karin Innes, Dr Helen Mutimer and Dr Brittany Howard (**FB Rice**)

Session 6: Emerging Private Companies & IPOs

Recently listed companies as well as private companies that will potentially list over the next 18 months will be featured in this session.

10.30am - 10.45am **ASX** (Sponsor introduction)
10.45am - 11.05am Malcom McColl, CEO of **ImmVirX**
11.05am - 11.25am Ian Nisbet & Alan Trounson, COO & CEO of **Cartherics**
11.25am - 11.45am Damian Clarke-Bruce, CEO of **HaemaLogix**
11.45am - 12.05pm Will Knox, CEO of **Tetratherix**
12.05pm - 12.25am Stephen Doyle, CEO of **Qbiotics Group**

Session 7: Refocusing for Results

Most companies at some point need to refocus their business plans or reprioritise their programs to drive shareholder value.

12.30pm - 12.50pm Cheryl Maley, CEO of **Starpharma Holdings**
12.50pm - 1.10pm Brent Barnes, CEO of **Clever Culture Systems**

1.10pm - 2.10pm **Lunch**



Session 7 Continued: Refocusing for Results

2.10pm - 2.30pm Kingsley Hall, CEO of **Micro-X**

Session 8: Diagnostics & Instrumentation

2.30pm - 2.50pm Tom Spurling, CEO of **Nova Eye Medical**
2.50pm - 3.10pm John Konstantopolous, Co-Founder of **Artrya**
Christos Papadimitriou, CEO of Tessara Therapeutics

3.10pm - 3.50pm **Break**

Session 9: Neurological Powerhouse Therapies

Neuren Pharmaceuticals has shown that the field of neurological disorders can be tackled successfully by Australian biotechs. The challenges are high, as are the potential rewards. CNS has become a very active field in global drug development, with multiple diseases being addressed by local companies. Led by Neuren, this session will look at the local CNS drug developers, their progress and the opportunities ahead.

3.50pm - 4.15pm Jon Pilcher, CEO of **Neuren Pharmaceuticals**
4.15pm - 4.35pm Liz Dallimore, CEO of **Argenica**
4.35pm - 4.55pm David Stamler, CEO of **Alterity Therapeutics**
4.55pm - 5.15pm James Bonnar, CEO of **Nyrada**
5.15pm - 5.20pm *David Kenley, CEO of Lateral Pharma*



Session 10: Investment Panel

In one of the most popular sessions at the Summit, we will ask leading sector analysts and investors on their views on where the sector is heading, and what stocks should attendees be looking at.

5.20pm - 5.50pm **Investment Panel**
Panelists: Tanushree Jain (Analyst at Petra Capital), Stuart Roberts (Pitt Street Research), Scott Power (Morgans), TBA

Chair: Cameron Jones, **Bio101**



5.50pm **Closing Comments**

7.00pm - late Conference Dinner (at Mures Seafood Restaurant, ticket required)



Media partner



IT Partner

